drugset / Trial / NCT01323218
Sleep Apnea Syndrome and Vitamin D
Phase 2
Unknown
80 enrolled
University Hospital, Clermont-Ferrand
Centre de Recherche en Nutrition Humaine Rhone-Alpe · collabCentre de Recherche en Nutrition Humaine d'Auvergne · collabLaboratoire Cidelec · collabLaboratoire Crinex · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Obstructive sleep apnea/hypopnea syndrome (OSAHS) is a highly prevalent disorder with multiple comorbidities. OSAHS is characterized by repetitive episodes of airflow reduction (hypopnoea) or cessation (apnoea) due to upper airway collapse during sleep. Its major risk factor is obesity. However, its pathogenesis is complex and multifactorial. Reduced upper airway muscle tonus and/or unstable neuromuscular output seem to be involved in this collapsus. A normal vitamin D status is necessary for normal muscle function and neuromuscular output. As obesity is associated with a high rate of hypovitaminosis D, it appears of interest to evaluate the effect of vitamin D supplementation on OSAHS patients with vitamin D deficiency.
Timeline
- Start
- 2011-03
- Primary completion
- 2012-04
- Completion
- 2012-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 25 OH vitamin D | Unknown | 400000 iu | Oral |